Read Zacks_Analysts' blog in RSS
August 21, 2009
Share This
Masimo Corporation (MASI) announced that it has signed a new worldwide technology licensing agreement with GS Elektromedizinische Gerate G. Stemple GmbH that will enable the latter to integrate Masimo’s Rainbow SET Pulse CO-Oximetry into its corpuls patient monitoring modules.
GS Elektromedizinische Gerate G. Stemple GmbH is a leading German company that develops and manufactures innovative medical equipment for Emergency Medical Services (EMS) and intensive care. The company is a market leader in providing innovative EMS solutions throughout Europe. The company’s corpuls patient monitoring modules and defibrillators are used in the first aid treatment of patients suffering from sudden cardiac arrest.
Masimo’s Rainbow SET Pulse CO-Oximetry allows for continuous monitoring of hemoglobin, carbon monoxide, methemoglobin, PVI for fluid responsiveness, perfusion index and measure-through motion pulse oximetry.
The integration of the Rainbow SET Pulse CO-Oximetry will enhance the efficiency of GS GmbH’s defibrillators and patient monitoring systems that help EMS professionals detect and treat life-threatening conditions at an earlier stage.
Though the financial terms of the agreement have not been disclosed, we believe that the deal will enhance Masimo’s international revenues. Masimo Corporation develops, manufactures and markets a family of non-invasive blood monitoring systems that consist of a monitor, circuit board and sensors. The systems are primarily used to monitor blood oxygen saturation levels and protect against hypoxemia and hyperoxemia.
Hypoxemia, low blood-oxygen levels, can result in brain damage and death. Hyperoxemia, high-blood oxygen levels, can result in permanent eye-damage and blindness.
Masimo is a market leader in the pulse oximetry monitoring equipment market industry. The company's closest competitors are Haemonetics Corporation (HAE) and Becton, Dickinson and Company (BDX). During fiscal 2008, the company gained five additional points of market share, taking the total to 43.5%.
Read the full analyst report on "MASI"
Read the full analyst report on "HAE"
Read the full analyst report on "BDX"
Zacks Investment Research